Aprinoia Therapeutics (Aprinoia Therapeutics) Revenue

: $9.13 Mil (TTM As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

Aprinoia Therapeutics's revenue for the six months ended in Jun. 2023 was $9.03 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $9.13 Mil. Aprinoia Therapeutics's Revenue per Share for the six months ended in Jun. 2023 was $0.33. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Aprinoia Therapeutics Revenue Historical Data

The historical data trend for Aprinoia Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Revenue

0.55

0.39

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Revenue	-	0.30	0.10	9.03

Competitive Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Revenue Distribution

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Revenue falls into.

Aprinoia Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $9.13 Mil.

Aprinoia Therapeutics (NAS:APRI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Aprinoia Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines